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with unique enhancement and stabilization power. A new feature of
this system, the Device Motion Indicator (DMI), can detect the intra-
luminal device in the X-Ray image stream and measure its relative
axial movement in an enhanced and stabilized background. Using the
DMI feature in patients undergoing PCI, we measured the pre-
deployment, relative, intra-luminal stent axial movement in the
different coronary arteries and their sub-segments.
RESULTS 197 patients underwent regular PCI with the support of the
Sync-Rx system. 225 branch point sites (1.15  0.4 per patient, range 1
to 3) were identiﬁed. Median Longitudinal DMI was 2.976mm 
0.45SE at the right coronary segments, 1.846mm  0.23SE at the LAD
segments and 2.22mm  0.4SE at the LCX segments. The Longitudinal
DMI values were higher in the mid (3.47mm) and distal (4.49mm)
segments of the RCA relative to the proximal part (1.90mm), higher in
the proximal part of the LAD (2.01mm) artery relative to the mid
(1.36mm) to distal parts (1.79mm), and higher in the mid and distal
parts of the LCX artery (2.56mm) relative to its proximal part
(1.71mm). The most movable segment in the coronary artery bed is the
distal part of the RCA, followed by the mid part of the RCA. Both heart
rate and left ventricular function signiﬁcantly affect DMI; the lower
the heart rate and the higher the cardiac function, the higher the DMI
values.
CONCLUSIONS In this paper we shed light for the ﬁrst time on the
entity of DMI and we propose it as a fundamental contributor for GM
phenomena. At the event of stent deployment at least two major pa-
rameters jeopardize optimal positioning: ﬁrst, the determining of the
lesion’s dimensions is mostly subjective and inaccurate, and second,
the working platform is a dynamic rather than a static one; the former
two parameters are adequately addressed by the Sync-Rx System. In
the era of the Sync-Rx System we are provided with the lesion di-
ameters and length, and with the online availability of the DMI, we
have the privilege and the capability to take advantage of this tool by
translating the DMI to extra stent length to better cover the presum-
ably diseased segment and avoid GM with its hazardous
consequences.
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BACKGROUND The optimal technique for crossing coronary chronic
total occlusions (CTOs) remains controversial. We sought to evaluate
the impact of crossing strategy on the incidence of periprocedural
myocardial infarction (MI) during CTO percutaneous coronary inter-
vention (PCI).
METHODS We retrospectively examined the incidence of periproce-
dural MI among 184 consecutive patients who underwent CTO PCI at
our institution between January 2012 and May 2015. Creatine kinase-
myocardial band fraction (CK-MB) and troponin I were measured both
before and after PCI in all patients. Periprocedural MI was deﬁned as
CK-MB increase 3x the upper limit of normal.
RESULTS Mean age was 65  8 years, and 98% of patients were men.
Overall, 57% of patients had diabetes mellitus, 36% were current
smokers, 38% had prior heart failure, 31% had prior coronary artery
bypass graft surgery, 55% had prior PCI, and 46% had prior MI.
Antegrade wire escalation, antegrade dissection/re-entry, retrograde,
and both retrograde and antegrade dissection/re-entry were used in
35%, 27%, 16%, and 22% of cases, respectively. Compared with ante-
grade wire escalation and antegrade dissection/re-entry, use of the
retrograde approach was associated with higher J-CTO scores, higher
rates of moderate or severe calciﬁcation (p¼0.026), longer occlusion
length (p<0.0001), more frequent proximal cap ambiguity (p<0.0001),
lower technical and procedural success, and higher incidence of per-
iprocedural MI (Table).Table. Lesion characteristics and outcomes of chronic total occlusion percutaneous coronary interventions,
classiﬁed according to crossing technique used.VariableOverall
(n[184)Antegrade
(n[65)Retrograde
(n[30)Antegrade
dissection/
re-entry
(n[50) PRetrograde
and
Antegrade
dissection/
re-entry
(n[39)J-CTO score 2.40  1.08 2  1.1 3.03  0.81 2.12  0.87 <0.0001 2.95  1.05
Technical
success, %93 98 87 98 0.018 85Procedural
success, %91 97 83 96 0.031 82Periprocedural
Myocardial
infarction, %19 11 33 10 0.008 33Major Adverse
Cardiovascular
Events, %3 2 7 2 0.306 3Post-PCI Peak
Troponin,
ng/mL0.52 (0.15,
1.63)0.31 (0.04,
1.05)1.06 (0.41,
3.68)0.26 (0.08,
0.86)0.0003 1.28 (0.49,
4.93)CONCLUSIONS As compared with antegrade wire escalation and
antegrade dissection/re-entry, the retrograde approach is used in
patients with more complex anatomy but carries threefold higher risk
for periprocedural MI.
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BACKGROUND Cardiac allograft vasculopathy (CAV) after cardiac trans-
plantation is characterized by diffuse and progressive intimal thickening
and is a major contributor to graft failure. Percutaneous coronary inter-
vention (PCI) has been considered palliative due to poor clinical outcomes
and high restenosis rates as informed by studies using older generation
stents, and has not been established as a viable alternative to the deﬁnitive
therapy of re-transplantation. However, second-generation everolimus-
eluting stents (EES) have demonstrated improved lesion patency in native
hearts and we sought to examine the long-term clinical and angiographic
outcomes of PCI with EES for the treatment of CAV.
METHODS Cardiac transplant patients with hemodynamically signif-
icant CAV (angiographic diameter stenosis 70%, left main 50%)
underwent PCI using EES. Surveillance angiography was performed at
6-12 months post-PCI, and then subsequently as clinically indicated.
Primary end-points were binary restenosis, target vessel revasculari-
zation (TVR), and target lesion revascularization (TLR). Quantitative
coronary angiography (QCA) was used to measure stent dimensions at
index PCI and follow-up angiograms.
RESULTS A total of 24 patients were included in this study, and 57
lesions were treated with 61 EES. Two stents were placed in the left
main, 26 in the left anterior descending, 15 in the right coronary, and
14 in the left circumﬂex artery. The average stent length and diameter
were 17.36.27mm and 2.930.56mm, respectively. Procedural suc-
cess rate was 100%. Mean length of follow-up was 20.815.0 months.
Over the entire follow-up study, binary restenosis occurred in 4/61
stents (6.56%), TLR in 5/57 lesions (8.8%), and TVR in 17/45 vessels
(37.8%). Clinical and angiographic follow-up are summarized in
Table 1. Lesion diameter stenosis (71.815.0%) was decreased after
PCI (9.034.14%) p<0.01 as assessed by QCA, an effect retained at
follow-up (13.112.9)% p<0.01. Minimal lumen diameter
(0.680.37 mm) was increased after PCI (2.530.66 mm) p<0.01, an
effect also retained at follow-up (2.420.66 mm) p<0.01.
CONCLUSIONS The use of EES for the treatment of CAV is associated
with a low long-term binary restenosis and TLR rate, comparable to
rates observed in native coronary arteries. However, there is a sig-
niﬁcant need for TVR, reﬂective of the diffuse and progressive nature
of CAV. Further investigation is warranted to assess whether treat-
ment of CAV with EES is associated with improved graft survival.
B186 J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5Number of patients 24Number of lesions treated 57Number of stents placed 61Stent length, diameter (mm) 17.36.27mm, 2.930.56mm
Length of follow-up 20.815.0 months
Retransplantation 1/24MI/Mortality 1/24Angiographic Follow-up 6-12mo 2y 3y 4y
Binary restenosis 4.91% (3/61) 5.13% (2/39) 6.25% (2/32) 11.8% (2/17)Target lesion revascularization 7.02% (4/57) 5.41% (2/37) 6.67% (2/30) 12.5% (2/16)Quantitative coronary angiography (QCA)Pre-procedure Post-procedure* Follow-upy p-valueReference vessel diameter (mm) 2.520.77 2.790.72 2.760.57 *<0.01, y0.02
Minimal lumen diameter (mm) 0.680.37 2.530.66 2.420.66 *<0.01, y<0.01
Diameter stenosis (%) 71.815.0 9.034.14 13.112.9 *<0.01, y<0.01Paired t-test for pre-procedural values compared to post-procedure*, follow-upy
CATEGORIES CORONARY: PCI Outcomes
KEYWORDS Cardiac allograft vasculopathy, Drug-eluting stent, sec-
ond generation, Heart transplant
TCT-453
Four Years Clinical Outcomes of Overlapping Everolimus-Eluting Stents
compared with Sirolimus-Eluting Stents
Dong-Bin Kim,1 Sung-Ho Her,2 Pum Joon Kim,1 Chul Soo Park,3
Jong Min Lee,4 Kiyuk Chang,5 Hee-Yeol Kim,6 Ki Dong Yoo,7
Doo Soo Jeon,8 Wook Sung Chung,9 Ki-Bae Seung5
1The Catholic University of Korea, Seoul, Korea, Republic of; 2Daejeon
St. Mary’s Hospital, Daejeon, Daejeon; 3Yeouido St Mary’s Hospital,
Seoul, Korea, Republic of; 4The Catholic University of Korea, Uijeongbu
St Mary’s Hospital, Gyeonggi-do, Korea, Republic of; 5The Catholic
University of Korea, Seoul St. Mary’s Hospital, Seoul, Korea, Republic
of; 6Division of Cardiology, The Catholic University of Korea, Bucheon,
Korea, Republic of; 7The Catholic University of Korea, St Vincent’s
Hospital, Gyeonggi-do, Korea, Republic of; 8The Catholic University of
Korea, Incheon St Mary’s Hospital, Incheon, Korea, Republic of; 9N/A,
South Korea
BACKGROUND The long-term safety and efﬁcacy of stent overlap
with second-generation drug-eluting stents (DES) have not been well
established. We evaluated long-term clinical outcomes of overlapping
everolimus-eluting stent (EES), as compared with sirolimus-eluting
stent (SES).
METHODS This study was conducted on a multicenter database of
percutaneous coronary intervention with DES. 903 Patients (SES,
n¼537; EES, n¼366) were enrolled based on the following inclusion
criteria: (1) patient receiving two overlapping SES or EES, and (2)
follow-up period of at least four years. We evaluated major adverse
cardiovascular event (MACE), deﬁned as the composite of all-cause
death, non-fatal myocardial infarction (MI) or target lesion revascu-
larization (TLR).
RESULTS During the four years, follow-up EES showed a lower rate of
MACE and TLR rate, as compared to SES (13% vs. 19%, p¼0.027; 3% vs.
7% p¼0.014, respectively). All-cause deaths and non-fatal MI rates
were not signiﬁcantly different between the EES and SES groups (9%
vs. 9%, p¼0.734; 2% vs. 3%, p¼0.259, respectively). After propensity-
score matching, the MACE and TLR of rate of EES group were signif-
icantly lower than those of SES group.
CONCLUSIONS Overlapping EES showed a signiﬁcant lower rate in
MACE and TLR, as compared to SES, in the long-term clinical follow-
up.
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BACKGROUND Aspirin forms a crucial backbone of the Antiplatelet
pharmacotherapy in patients undergoing percutaneous coronaryintervention (PCI). However, there is uncertainty regarding the
optimal dose to be prescribed. We aim to perform a systematic liter-
ature review on all studies comparing treatment with low and high
dose aspirin in patients undergoing PCI.
METHODS A comprehensive literature search was performed by 2
independent reviewers utilizing MEDLINE, EMBASE and Cochrane
Library databases. All trials comparing low dose and high dose aspirin
in patients undergoing PCI were selected. Low dose was deﬁned
as <162mg and high dose as 162mg. Outcomes measured included
major adverse cardiovascular events (MACE), deﬁned as the
composite of death, reinfarction, stroke and target vessel revascular-
ization, and bleeding. In combining evidence across the trials, a ﬁxed-
effect method in RevMan 5.3 was used after ruling out heterogeneity
based on the I2 test (I2<40%) to obtain hazards ratios for the
outcomes.
RESULTS Five studies with a total of 27,456 patients were selected.
Two studies evaluated outcomes at 30 days and three studies at 1
year. No signiﬁcant difference was found in MACE rates when eval-
uating low dose against high dose aspirin (HR [95% CI], 1.03 [0.93-
1.15]; p¼0.55). Bleeding rates were signiﬁcantly lower in the low dose
aspirin group as compared to the high dose group (HR [95% CI], 0.64
[0.50-0.83]; p¼0.0005). Two studies reporting stent thrombosis rates
did not show any difference between both groups.
CONCLUSIONS Although there was no signiﬁcant difference in MACE
rates between the high and low dose aspirin groups, the high dose
aspirin group appeared to be at a signiﬁcantly increased risk of
bleeding complications. This lends weight to the use of low dose
aspirin in patients undergoing PCI.
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BACKGROUND Whether a smoker’s paradox exists with regards to
early and late mortality outcomes for patients undergoing percuta-
neous coronary intervention (PCI) for acute coronary syndrome (ACS)
is debated. Studies have produced inconclusive data on whether such
a paradox exists or whether it can be explained by confounding
